508 related articles for article (PubMed ID: 24439760)
21. ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION: Role of Prophylactic Topical Ophthalmic Antibiotics.
Li AL; Wykoff CC; Wang R; Chen E; Benz MS; Fish RH; Wong TP; Major JC; Brown DM; Schefler AC; Kim RY; OʼMalley RE
Retina; 2016 Jul; 36(7):1349-56. PubMed ID: 26655622
[TBL] [Abstract][Full Text] [Related]
22. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.
Rayess N; Rahimy E; Storey P; Shah CP; Wolfe JD; Chen E; DeCroos FC; Garg SJ; Hsu J
Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277
[TBL] [Abstract][Full Text] [Related]
23. Endophthalmitis after intravitreal injection: the importance of viridans streptococci.
Chen E; Lin MY; Cox J; Brown DM
Retina; 2011 Sep; 31(8):1525-33. PubMed ID: 21878800
[TBL] [Abstract][Full Text] [Related]
24. Open globe injuries with positive intraocular cultures: factors influencing final visual acuity outcomes.
Lieb DF; Scott IU; Flynn HW; Miller D; Feuer WJ
Ophthalmology; 2003 Aug; 110(8):1560-6. PubMed ID: 12917173
[TBL] [Abstract][Full Text] [Related]
25. Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch.
Yamashiro K; Tsujikawa A; Miyamoto K; Oh H; Otani A; Tamuara H; Ooto S; Sasahara M; Iwama D; Yoshimura N
Retina; 2010 Mar; 30(3):485-90. PubMed ID: 19952993
[TBL] [Abstract][Full Text] [Related]
26. Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration.
Wickremasinghe SS; Michalova K; Gilhotra J; Guymer RH; Harper CA; Wong TY; Qureshi S
Ophthalmology; 2008 Nov; 115(11):1911-5. PubMed ID: 18672291
[TBL] [Abstract][Full Text] [Related]
27. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
28. Postinjection endophthalmitis in the comparison of age-related macular degeneration treatments trials (CATT).
Meredith TA; McCannel CA; Barr C; Doft BH; Peskin E; Maguire MG; Martin DF; Prenner JL;
Ophthalmology; 2015 Apr; 122(4):817-21. PubMed ID: 25600198
[TBL] [Abstract][Full Text] [Related]
29. Endophthalmitis caused by Streptococcus pneumoniae.
Miller JJ; Scott IU; Flynn HW; Smiddy WE; Corey RP; Miller D
Am J Ophthalmol; 2004 Aug; 138(2):231-6. PubMed ID: 15289132
[TBL] [Abstract][Full Text] [Related]
30. Intravitreal injections at the Massachusetts Eye and Ear Infirmary: analysis of treatment indications and postinjection endophthalmitis rates.
Englander M; Chen TC; Paschalis EI; Miller JW; Kim IK
Br J Ophthalmol; 2013 Apr; 97(4):460-5. PubMed ID: 23390167
[TBL] [Abstract][Full Text] [Related]
31. Bilateral simultaneous intravitreal injections in the office setting.
Bakri SJ; Risco M; Edwards AO; Pulido JS
Am J Ophthalmol; 2009 Jul; 148(1):66-9.e1. PubMed ID: 19403114
[TBL] [Abstract][Full Text] [Related]
32. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
33. Severe intraocular inflammation after intravitreal injection of bevacizumab.
Sato T; Emi K; Ikeda T; Bando H; Sato S; Morita S; Oyagi T; Sawada K
Ophthalmology; 2010 Mar; 117(3):512-6, 516.e1-2. PubMed ID: 20031229
[TBL] [Abstract][Full Text] [Related]
34. Streptococcus mitis endophthalmitis presenting as frosted branch angiitis after intravitreal pegaptanib sodium injection.
Chen E; Ho AC; Garg SJ; Brown GC; Kaiser RS
Ophthalmic Surg Lasers Imaging; 2009; 40(2):192-4. PubMed ID: 19320312
[TBL] [Abstract][Full Text] [Related]
35. Changes in Management Based on Vitreous Culture in Endophthalmitis After Intravitreal Anti-vascular Endothelial Growth Factor Injection.
Patel SN; Storey PP; Pancholy M; Obeid A; Wibbelsman TD; Levin H; Hsu J; Garg SJ; Dunn JP; Vander JF
Am J Ophthalmol; 2019 Nov; 207():224-231. PubMed ID: 31201794
[TBL] [Abstract][Full Text] [Related]
36. Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion.
Singer MA; Bell DJ; Woods P; Pollard J; Boord T; Herro A; Porbandarwalla S
Retina; 2012 Jul; 32(7):1289-94. PubMed ID: 22466480
[TBL] [Abstract][Full Text] [Related]
37.
Beri S; Shandil A; Garg R
Indian J Ophthalmol; 2017 Nov; 65(11):1166-1171. PubMed ID: 29133644
[TBL] [Abstract][Full Text] [Related]
38. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
[TBL] [Abstract][Full Text] [Related]
39. Endophthalmitis after Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors: Management and Visual Outcomes.
Xu K; Chin EK; Bennett SR; Williams DF; Ryan EH; Dev S; Mittra RA; Quiram PA; Davies JB; Parke DW; Johnson JB; Cantrill HL; Almeida DRP
Ophthalmology; 2018 Aug; 125(8):1279-1286. PubMed ID: 29477689
[TBL] [Abstract][Full Text] [Related]
40. Infectious and noninfectious endophthalmitis after intravitreal bevacizumab.
Jonas JB; Spandau UH; Rensch F; Von Baltz S; Schlichtenbrede F
J Ocul Pharmacol Ther; 2007 Jun; 23(3):240-2. PubMed ID: 17593007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
